BioXcel Therapeutics Announces Termination of Proposed Public …

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …

CouponFollow Extension

$60
OFF

BioXcel Therapeutics Terminates $60 Mln Proposed Public Offering

6 days from now

Feb 13, 2024 · (RTTNews) - Tuesday, BioXcel Therapeutics, Inc. (BTAI) announced the termination of its proposed public offering of $60 million in common stock which was …

businessinsider.com

$60
OFF

BioXcel Therapeutics (BTAI) Terminates Proposed $60M Offering

6 days from now

Feb 13, 2024 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of …

streetinsider.com

$60
OFF

BioXcel Therapeutics Announces Termination Of Proposed Public …

6 days from now

BioXcel Therapeutics (NASDAQ: BTAI) on Tuesday said it has terminated its proposed public offering of $60 million of shares of its common stock or, pre-funded warrants to purchase …

msn.com

$60
OFF

BioXcel Therapeutics Calls Off Proposed $60M Public Offering

6 days from now

Feb 13, 2024 · Less than a week after announcing plans to raise $60 million from inventors, New Haven-based BioXcel Therapeutics Inc. said Tuesday it’s calling off the proposed public offering.

hartfordbusiness.com

$60
OFF

BioXcel Therapeutics Terminates $60 Mln Proposed Public Offering

6 days from now

STOCK ALERTS BioXcel Therapeutics Terminates $60 Mln Proposed Public Offering 2/13/2024 10:37 AM Tuesday, BioXcel Therapeutics, Inc. (BTAI) announced the termination of its …

rttnews.com

$60
OFF

BioXcel Therapeutics Announces Termination Of Proposed Public …

6 days from now

Feb 13, 2024 · BioXcel Therapeutics, Inc. today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to …

biospace.com

$60
OFF

FX.co - BioXcel Therapeutics Terminates $60 Mln Proposed Public ...

6 days from now

Feb 13, 2024 · On Tuesday, BioXcel Therapeutics, Inc. announced the cancellation of its proposed public offering of $60 million in common stock, which was initially announced on …

fx.co

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million Public …

6 days from now

20 hours ago · Gross proceeds to the Company from the offering are expected to be approximately $7.0 million, before deducting underwriting discounts and commissions and …

businessinsider.com

$60
OFF

BioXcel Therapeutics Announces $60M Proposed Public Offering

6 days from now

Feb 9, 2024 · BioXcel Therapeutics Inc. a New Haven-based biopharmaceutical company, announced a $60 million proposed public offering on Thursday.

hartfordbusiness.com

$7
OFF

BioXcel Therapeutics Announces $7M Public Offering

6 days from now

19 hours ago · BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company that uses artificial intelligence to develop medicines in neuroscience and immuno-oncology, on …

hartfordbusiness.com

FAQs about BioXcel Therapeutics Announces Termination of Proposed Public … Coupon?

What happened to bioxcel Therapeutics (btai)?

(RTTNews) - Tuesday, BioXcel Therapeutics, Inc. (BTAI) announced the termination of its proposed public offering of $60 million in common stock which was previously announced on February 8, 2024. Following this news stock gained 11%. ...

Who owns bioxcel Therapeutics?

Private Companies own 31% of the shares in BioXcel Therapeutics, Inc. (NASDAQ:BTAI). The general public holds a 24% stake in the company, but they may not have enough influence to sway policy decisions. ...

Will BioXcel Therapeutics lose value?

If things turn out that way, BioXcel Therapeutics will lose a substantial percentage of its value. We will know soon enough whether this is the case and if the company's ongoing launch of Igalmi in its current indication could come short of expectations. ...

Is BioXcel Therapeutics profitable?

BioXcel Therapeutics is likely to remain unprofitable despite Igalmi generating more revenue due to increased expenses related to its launch and clinical programs. ...